Researchers are reporting progress in the race to develop a safe and effective vaccine against the new coronavirus. The disease it causes, COVID-19, has killed at least 610,000 people worldwide. More than 14.7 million people have been infected.

    Two different experimental vaccines have produced strong immune reactions in people involved in the studies. And neither produced serious unwanted effects. The separate research was published Monday in the British medical journal The Lancet.

    The most promising of the two preventative medicines comes from a partnership between Oxford University in Britain and drug maker AstraZeneca. The company has signed agreements with many governments to supply its vaccine if it proves to be effective and wins legal approval. AstraZeneca has promised to make 2 billion vaccine treatments.

    The New York Times newspaper reports that the vaccine has been given to more than 10,000 volunteers in Britain, Brazil and South Africa. It says 30,000 people in the United States are to receive the experimental vaccine next week.
    《纽约时报》报道称,已经给英国、巴西和南非的1万多名志愿者接种了这种疫苗。该报道称 下周将有3万美国人接种这种实验性疫苗。

    The drug company CanSinoBiologics Incorporated and the Chinese military is developing the other vaccine. It was tested on 508 healthy volunteers who received one treatment each, the researchers reported. Most of those tested showed a good immune reaction.

    About 77 percent of the volunteers reported temporary side effects, including increased body temperature and pain at the place of injection. None of the side effects were severe or unusual, the researchers reported.

    Both the AstraZeneca and CanSino vaccines use a harmless adenovirus to carry genetic material from the new coronavirus into the body.

    "Overall, the results of both trials are broadly similar and promising," Naor Bar-Zeev and William Moss wrote in The Lancet. Both writers are vaccine experts at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.
    Naor Bar-Zeev和William Moss在柳叶刀杂志上写道:“总体而言, 这两项试验的结果大致相同并且颇有希望。”这两位作者是马里兰州巴尔的摩市霍普金斯大学彭博公共卫生学院的疫苗专家。

    Also Monday, the drug maker Pfizer and its partner BioNTech reported success on their vaccine candidate. That study was small, involving 60 healthy adults. Outside experts have not yet examined the research findings.

    Last week, the medical research company Moderna announced strong immune reaction in tests of a vaccine developed by researchers at the U.S. National Institute of Allergy and Infectious Diseases. However, the volunteers involved in that research reported more unwanted effects such as tiredness, head pain, chills and muscle pain.
    上周,Moderna医学研究公司宣布,由美国国家过敏和传染病研究所的研究人员开发的疫苗在测试中产生了很强的免疫反应。 但是,参与该研究的志愿者报告了更多的不良反应,例如疲劳、头痛、发冷和肌肉疼痛。

    Dr. Peter Hotez is an infectious diseases expert at Baylor College of Medicine in Houston, Texas. On Monday, he told the American news group CNN that "the first vaccines may not be our best vaccines." Hotez said it would probably take another year to produce all the necessary evidence that the new coronavirus vaccines are safe and effective.
    Peter Hotez博士是德克萨斯州休斯顿贝勒医学院的传染病专家。他周一对美国有线电视网表示,“首批疫苗可能不是我们最好的疫苗。”Hotez表示,可能还要一年时间才能得出所有必要证据,来证实新冠病毒疫苗是安全有效的。

    Early Tuesday, European leaders agreed on a $2.1-trillion budget. The agreement includes $857 billion in coronavirus support that will be issued as loans and aid to the hardest-hit countries.

    I'm Caty Weaver.